Novartis Venture Fund Parent: Novartis

Founded 1996
Employees 10+
Primary contact
Novartis International AG, P.O. Box
4002 Basel
Switzerland
Novartis Venture Fund (NVF) is a stage-agnostic venture arm of Novartis, engaging in investments from seed- to later-stage life sciences companies across Biotechnology/Biopharma, Medical Devices, and Diagnostics. Its primary focus is on the development of novel therapeutics and platforms, with a preference to either lead or co-lead an investment and play an active role on company boards. NVF's portfolio companies span North America, Europe, Israel, and Asia/Pacific.
Founded 1996
Employees 10+
Primary contact
Novartis International AG, P.O. Box
4002 Basel
Switzerland

Key people ๐Ÿง‘โ€๐Ÿคโ€๐Ÿง‘

Investments ๐Ÿ’ธ

Artios Pharma
Developer of cancer treatments that target DNA Damage Response pathways to selectively kill cancer cells
๐Ÿ“ Cambridge, United Kingdom
Splice Bio
Biotech company exploiting Protein Splicing to develop the next generation of gene therapies
๐Ÿ“ Barcelona, Spain
Tagworks Pharmaceuticals
Developer of click-cleavable ADC therapies for patients suffering from severe diseases, including cancer
๐Ÿ“ Nijmegen, Netherlands
Last update: November 1, 2022